Rochester Drug Co-Operative, Inc. v. Hiscox Insurance Company, Inc.

District Court, W.D. New York·Decided June 11, 2020·No. 6:20-cv-06025·Unknown

Opinion

UNITED STATES DISTRICT COURT WESTERN DISTRICT OF NEW YORK _____________________________________

ROCHESTER DRUG CO-OPERATIVE, INC.

Plaintiff, DECISION AND ORDER

v. 6:20-CV-06025 EAW

HISCOX INSURANCE COMPANY, INC.,

Defendant. _____________________________________

INTRODUCTION Plaintiff Rochester Drug Co-Operative (“Plaintiff”) brings an action against Hiscox Insurance Company, Inc. (“Defendant”) for breach of an insurance policy due to Defendant’s refusal to advance reasonable defense costs for a trial. (Dkt. 1). On January 24, 2020, Plaintiff filed a motion for preliminary injunction seeking an order pursuant to Federal Rule of Civil Procedure 65(a) enjoining and restraining defendant Hiscox Insurance Company, Inc. (“Defendant”) from “[d]ishonoring [Plaintiff’s] . . . right to the advancement of current and future defense costs, inclusive of attorneys’ fees, discovery expenses, and expert fees; and . . . [r]efusing to advance reasonable defense costs” in connection with three lawsuits scheduled to go to trial on March 20, 2020, in New York State Supreme Court, Suffolk County. (Dkt. 11). The Court issued an Order on February 25, 2020, granting Plaintiff’s motion subject to it posting a bond in the amount of five hundred thousand dollars ($500,000), and noting that a Decision and Order would subsequently be issued memorializing the Court’s reasoning in further detail. (Dkt. 44). Also presently before the Court is Defendant’s motion to dismiss pursuant to Federal Rule of Civil Procedure 12(b)(6). (Dkt. 21)

The Court now issues this Decision and Order setting forth in further detail its reasons for previously granting Plaintiff’s motion for preliminary injunction, and for those same reasons, it now denies Defendant’s motion to dismiss. FACTUAL AND PROCEDURAL BACKGROUND Plaintiff is a drug distribution cooperative owned by and run for the benefit of independent pharmacies. (Dkt. 11-3 at ¶ 3). Plaintiff purchases pharmaceuticals directly

from manufacturers and distributes them to licensed pharmacies throughout the northeast. (Id.). Headquartered in Rochester, Plaintiff employed a total of 183 employees, including 97 in Rochester. (Id.). Over the past two years, Plaintiff has been sued, alongside other drug distributors, in more than thirty-one actions throughout the state of New York, both state and federal,

for its alleged involvement in the unlawful distribution of opioids (“NY Opioid Lawsuits”). (Dkt. 11-1 at ¶ 6). These cases include three actions brought by Nassau County, Suffolk County, and the State of New York (the “Trial Litigation”). (Dkt. 11-3 at ¶¶ 6, 10). In July 2015, the U.S. Attorney’s Office for the Southern District of New York filed a civil action against Plaintiff based on Plaintiff’s failure to file required reports with the

U.S. Drug Enforcement Agency (“DEA”). (Dkt. 11-1 at 234). On July 8, 2015, a consent order was entered where Plaintiff admitted to violations of the Controlled Substances Act regarding its failure to report and agreed to pay a $360,000 penalty. (Id.). In February 2017, the Government served a civil document request on Plaintiff seeking documents related to its distribution of controlled substances. (Id. at 242).

On February 1, 2017, Plaintiff submitted a completed AIG Portfolio Select Application for an insurance policy to Defendant (the “Application”). (Dkt. 20). In March 2017, Plaintiff purchased Private Company Management Liability Insurance Policy No. UVA 1901769.17 from Defendant, effective from March 8, 2017, to March 8, 2018 (the “Policy”). (Dkt. 1-1 at 22-147). Defendant agreed under the Policy to pay up to $5,000,000 for defense costs incurred to defend Plaintiff against covered claims and an additional

executive limit of liability of $1,000,000, subject to a $25,000 retention. (Id. at 2, 74). The Policy includes “wrongful acts” coverage, defining a “wrongful act” to include “any breach of duty, neglect, error, misstatement, misleading statement, omission, or act.” (Id. at 19). The Policy also contains an exclusion for “any Claim . . . arising out of, based upon or attributable to the . . . committing of any deliberate criminal or deliberate fraudulent act . . .

if any final adjudication establishes that such deliberate criminal or deliberate fraudulent act . . . was committed.” (Id. at 20). In November 2017, Plaintiff retained the law firm Allegaert Berger & Vogel LLP (“ABV”) to represent it in the NY Opioid Litigation brought by the New York Attorney General and various New York counties and municipalities (“State Actions”).1 (Dkt. 11-2

1 ABV was further retained on March 27, 2019, to represent Plaintiff in connection with opioid-related cases filed in the federal multidistrict litigation styled In re: National Prescription Opiate Litigation, MDL 2804, currently pending before Judge Dan A. Polster in the Northern District of Ohio. (Dkt. 11-2 at ¶ 6). at ¶ 6). Also in November 2017, the U.S. Attorney served a criminal subpoena on Plaintiff. (Dkt. 11-1 at 242).

Plaintiff notified Defendant of two of the state court lawsuits, and on March 22, 2018, Defendant acknowledged potential coverage for those lawsuits “subject to the Policy’s terms and conditions, currently known information and a full reservation of rights.” (Dkt. 11-3 at 8-15). Thereafter, Plaintiff provided Defendant notice of at least 25 other actions, and on August 24, 2018, Defendant once again acknowledged potential coverage for those matters. (Id. at 17-22). On October 2018, ABV submitted an estimated

litigation plan and budget to Defendant. (Id. at ¶ 7). Before this submission, Defendant had attempted repeatedly to get copies of ABV’s invoices and to discuss allocation between covered and uncovered claims. (Dkt. 17 at 18). On January 18, 2019, Plaintiff’s broker informed Defendant that Plaintiff’s general counsel would address allocation, but Defendant was never contacted by the general counsel. (Dkt. 17-6). On February 19, 2019,

Defendant issued a letter acknowledging potential coverage for two additional actions. (Dkt. 11-1 at 338-44). On April 22, 2019, Plaintiff entered into a deferred prosecution agreement (“DPA”) with the U.S. Attorney for the Southern District of New York. (Dkt. 11-1 at 171-299). The DPA included admissions of wrongdoing by Plaintiff, and provided for the dismissal of the

information with prejudice after five years’ compliance with the terms of the agreement. (Id.). On April 23, 2019, Plaintiff stipulated to a civil settlement with the U.S. Attorney for the Southern District of New York (the “Stipulation”), which also contained admissions of wrongdoing and provided that Plaintiff will obtain a release of liability if it complied with the Stipulation’s terms, and that a judgment would be filed only “[i]n the event of an Uncured Default” of the Company’s settlement payments. (Id. at 306-25). The Stipulation

was “So Ordered” by the United States District Judge on April 25, 2019. (Id. at 325). On May 3, 2019, William Pietruszewski, Plaintiff’s former Chief of Compliance, pleaded guilty in the United States District Court for the Southern District of New York to violations of 21 U.S.C. § 841(a)(1) for conspiracy to distribute narcotics, 18 U.S.C. § 371 for conspiracy to defraud the United States, and 21 U.S.C. §§ 842(a)(5) and (c)(2)(A) for knowingly failing to report narcotic sales. United States v.

Free access — add to your briefcase to read the full text and ask questions with AI

Rochester Drug Co-Operative, Inc. v. Hiscox Insurance Company, Inc., (W.D.N.Y. 2020).

Rochester Drug Co-Operative, Inc. v. Hiscox Insurance Company, Inc. (Rochester Drug Co-Operative, Inc. v. Hiscox Insurance Company, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Bryan v. United States
524 U.S. 184 (Supreme Court, 1998)
Cacchillo v. Insmed, Inc.
638 F.3d 401 (Second Circuit, 2011)
Nokia Corp. v. InterDigital, Inc.
645 F.3d 553 (Second Circuit, 2011)
Jackson Dairy, Inc. v. H. P. Hood & Sons, Inc.
596 F.2d 70 (Second Circuit, 1979)
Johnson v. Kay
860 F.2d 529 (Second Circuit, 1988)